January 6, 2022

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

BOSTON and SHANGHAI, January 6, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of John Orloff, MD to its Board of Directors. Dr. Orloff joins the Zenas Board with over 25 years of experience successfully leading global research and development organizations across multiple therapeutic areas including autoimmune diseases.

“We are extremely pleased to welcome Dr. Orloff to the Zenas Board of Directors,” said Lonnie Moulder, Founder and Executive Chairman of Zenas. “John’s leadership and extensive expertise in research, development, and medical and regulatory affairs will be invaluable as we advance our portfolio of innovative immune-based therapeutics and continue to expand our pipeline via business development.”

“I am delighted to work with the Zenas leadership team and fellow directors as the Company rapidly progresses an exciting immune-based pipeline.” said Dr. Orloff. “I look forward to contributing to the Company’s continued development as it strives to deliver on its mission to bring innovative medicines to patients in need.”

Dr. Orloff currently serves as a venture partner with Agent Capital. In his most recent executive role, he served as Executive Vice President and Head of Research and Development at Alexion where his leadership in expanding the development pipeline to 30 programs supported the recent $39 billion acquisition of Alexion by AstraZeneca.

Prior to Alexion, Dr. Orloff served as Global Head of R&D and Chief Scientific Officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Before entering the biopharmaceutical industry, he was a faculty member of the Yale University School of Medicine. Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

关于Zenas BioPharma

Zenas BioPharma是一家跨国(美国-中国)生物制药公司,致力于成为中国和世界各地患者免疫疗法开发和交付的全球领先企业。Zenas的创新治疗药物深度研发管线正在快速推进,并通过我们成功的业务发展战略不断发展。我们经验丰富的领导团队和我们的业务合作伙伴网络将推动卓越运营,以提供潜在的变革性疗法来改善自身免疫性疾病和罕见疾病患者的生活。” 要了解有关Zenas BioPharma的更多信息,请访问www.zenasbio.com,并通过Twitter(@ZenasBioPharma)LinkedIn关注我们。

联系人

投资者关系联系方式:
Zenas BioPharma
IR@zenasbio.com

媒体联系人:
Lauren Bartlett
Zenas BioPharma
lauren.bartlett@zenasbio.com

long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands